A quick map of what's well-established about SYNGAP1-Related Disorder versus what's still genuinely open — across seven knowledge domains and the three broad classes of variant. Compiled from peer-reviewed literature, GeneReviews, and (where noted) trial/registry sources. Click any cell for the evidence behind it.
This page follows the same citation bar as the rest of this app: peer-reviewed literature, GeneReviews, ClinicalTrials.gov, UniProt, Orphanet, and NORD are treated as primary sources; foundation/advocacy sources are used only for supporting context and are labeled explicitly wherever they appear.
A few honest limits from compiling this: several primary sources (Wiley/Clinical Genetics, ScienceDirect, some journal sites) blocked automated access during research, so those citations rely on verified titles/abstracts rather than confirmed full text — noted individually below. Clinical-trial-pipeline status for the most advanced treatment candidate is currently sourced to company press releases and trade press, not to a confirmed ClinicalTrials.gov registry entry or peer-reviewed publication. One prevalence estimate is sourced to an advocacy-org summary of a model that couldn't be independently verified against its original peer-reviewed publication in this pass.
This is a snapshot, not a living tracker — SYNGAP1-RD research is moving quickly, and some of what's marked "largely unknown" here may already be better understood by the time you're reading this. Always check the original sources.
Rows are knowledge domains. Columns are the three broad classes of SYNGAP1 variant. Tap/click a colored cell to open the evidence and citations behind that rating.